Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Maithel, Ipek Coban, P. Kneuertz, D. Kooby, B. El-Rayes, J. Kauh, J. Sarmiento, C. Staley, N. Adsay (2011)
Differential Expression of ERCC1 in Pancreas Adenocarcinoma: High Tumor Expression is Associated with Earlier Recurrence and Shortened Survival after ResectionAnnals of Surgical Oncology, 18
E. Reed (1998)
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.Cancer treatment reviews, 24 5
N. Siddaraju (2021)
Malignant pleural mesothelioma: A guide for cliniciansThe Indian Journal of Medical Research, 153
D. Shersher, M. Liptay (2013)
Multimodality treatment of pleural mesothelioma.Surgical oncology clinics of North America, 22 2
Peters (2014)
435Anticancer Res, 34
J. Weberpals, K. Garbuio, A. O'Brien, K. Clark-Knowles, S. Doucette, Olga Antoniouk, G. Goss, J. Dimitroulakos (2009)
The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancerInternational Journal of Cancer, 124
D. Zamble, D. Mu, J. Reardon, A. Sancar, S. Lippard (1996)
Repair of cisplatin--DNA adducts by the mammalian excision nuclease.Biochemistry, 35 31
(2007)
ERRC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer
Zhong Zheng, Tingan Chen, Xueli Li, E. Haura, Anupama Sharma, G. Bepler (2007)
DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.The New England journal of medicine, 356 8
G. Ceresoli, P. Zucali, F. Vincenzo, L. Gianoncelli, M. Simonelli, E. Lorenzi, C. Ripa, L. Giordano, A. Santoro (2011)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.Lung cancer, 72 1
C. Ban, Huanzhong Shi, Yu-hui Zhang (2017)
Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality TreatmentChinese Medical Journal, 130
S. Ting, F. Mairinger, T. Hager, S. Welter, W. Eberhardt, J. Wohlschlaeger, K. Schmid, D. Christoph (2013)
ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.Clinical lung cancer, 14 5
Tsao (2009)
2081J Clin Oncol, 27
F. Galateau-Salle, A. Churg, V. Roggli, W. Travis (2016)
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 11 2
L. Berzenji, P. Schil (2018)
Multimodality treatment of malignant pleural mesotheliomaF1000Research, 7
L. Jordheim, P. Sève, O. Trédan, C. Dumontet (2011)
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.The Lancet. Oncology, 12 7
G. Bepler, M. Begum, G. Simon (2008)
Molecular analysis-based treatment strategies for non-small cell lung cancer.Cancer control : journal of the Moffitt Cancer Center, 15 2
A. Nowak (2012)
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.Annals of cardiothoracic surgery, 1 4
A. Codegoni, M. Broggini, M. Pitelli, M. Pantarotto, V. Torri, C. Mangioni, M. D’Incalci (1997)
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.Gynecologic oncology, 65 1
Nowak (2012)
508Ann Cardiothorac Surg, 1
Z. Zimling, J. Sørensen, T. Gerds, C. Bech, C. Andersen, E. Santoni-Rugiu (2012)
Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free SurvivalJournal of Thoracic Oncology, 7
S. Scheil‐Bertram, Patricia Tylus-Schaaf, A. Bois, P. Harter, M. Oppitz, N. Ewald-Riegler, A. Fisseler‐Eckhoff (2010)
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.Gynecologic oncology, 119 2
L. Sad, S. Younis, Mohamed Elity (2014)
Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancerMedical Oncology, 31
G. Peters, Abolfazl Avan, M. Ruiz, V. Orsini, A. Avan, E. Giovannetti, E. Smit (2014)
Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer.Anticancer research, 34 1
B. Besse, K. Olaussen, J. Soria (2013)
ERCC1 and RRM1: ready for prime time?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 8
H. Akita, Z. Zheng, Yoshito Takeda, Chiwan Kim, N. Kittaka, S. Kobayashi, S. Marubashi, I. Takemasa, H. Nagano, K. Dono, S. Nakamori, Morito Monden, Masaki Mori, Y. Doki, G. Bepler (2009)
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinomaOncogene, 28
N. Vogelzang, J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffié, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, C. Niyikiza, P. Paoletti (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 14
Z. Zimling, E. Santoni-Rugiu, C. Bech, J. Sørensen (2015)
High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.Anticancer research, 35 12
Y. Cihan, A. Ozturk, A. Arslan, K. Deniz, M. Baran, H. Karaca (2014)
ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.Asian Pacific journal of cancer prevention : APJCP, 15 10
T. Powrózek, D. Kowalski, P. Krawczyk, R. Ramlau, Tomasz Kucharczyk, E. Kalinka‐Warzocha, M. Knetki-Wróblewska, K. Winiarczyk, W. Dyszkiewicz, M. Krzakowski, J. Milanowski (2014)
Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.Clinical lung cancer, 15 6
Guo Zhang, Jian Chen, Lin Wang, Jun Li, Ming Li, N. Xu, Yang Wang, J. Shentu (2012)
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancerCancer Chemotherapy and Pharmacology, 69
Lainie Martin, T. Hamilton, R. Schilder (2008)
Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 14
Zito Federica, Sabetta Rosalaura, Ronchi Andrea, M. Accardo, I. Angelillo, R. Franco (2019)
Molecular Mechanisms in the Pathogenesis of Malignant Pleural Mesothelioma: Predictive and Prognostic FactorsMalignant Pleural Mesothelioma
G. Simon, M. Schell, M. Begum, Jongphil Kim, A. Chiappori, E. Haura, S. Antonia, G. Bepler (2012)
Preliminary indication of survival benefit from ERCC1 and RRM1‐tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysisCancer, 118
K. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. André, V. Haddad, E. Taranchon, M. Filipits, R. Pirker, H. Popper, R. Stahel, L. Sabatier, J. Pignon, T. Tursz, T. Chevalier, J. Soria (2006)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.The New England journal of medicine, 355 10
R. Rosell, E. Felip, M. Taron, J. Majó, P. Méndez, M. Sánchez-Ronco, C. Queralt, J. Sánchez, J. Maestre (2004)
Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional SurgeryClinical Cancer Research, 10
A. Husain, T. Colby, N. Ordóñez, T. Allen, R. Attanoos, M. Beasley, K. Butnor, L. Chirieac, A. Churg, S. Dacic, F. Galateau-Salle, A. Gibbs, A. Gown, T. Krausz, L. Litzky, A. Marchevsky, A. Nicholson, V. Roggli, Anupama Sharma, W. Travis, A. Walts, M. Wick (2018)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.Archives of pathology & laboratory medicine, 142 1
Zhi-liang Huang, Xun Cao, Ruo-Zhen Luo, Youfang Chen, Lin-Chun Zhu, Z. Wen (2016)
Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.Oncology letters, 11 1
S. Chattopadhyay, R. Moran, D. Goldman (2007)
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applicationsMolecular Cancer Therapeutics, 6
Zimling (2015)
6731Anticancer Res, 35
Mónica SernaCamacho, Seir Alfonso (2017)
Malignant Pleural Mesothelioma
Booton (2007)
902J Clin Oncol, 2
M. Ulker, B. Duman, B. Şahin, D. Gumurdulu (2015)
ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabineContemporary Oncology, 19
Ulker (2015)
207Contemp Oncol (Pozn), 19
Dong Yan, P. Wei, G. An, Wenming Chen (2013)
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancerJournal of Cardiothoracic Surgery, 8
L. Friboulet, K. Olaussen, J. Pignon, F. Shepherd, M. Tsao, S. Graziano, R. Kratzke, J. Douillard, L. Seymour, R. Pirker, M. Filipits, F. André, E. Solary, Florence Ponsonnailles, Angélique Robin, A. Stoclin, N. Dorvault, F. Commo, J. Adam, Elsa Vanhecke, P. Saulnier, J. Thomale, T. Chevalier, A. Dunant, V. Rousseau, G. Teuff, E. Brambilla, J. Soria (2013)
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.The New England journal of medicine, 368 12
Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. To date, standard MPM therapy is still limited to surgery, radiotherapy, and chemotherapy, including pemetrexed and platinum compounds. The main mechanisms of platinum resistance are associated with DNA repair pathways. Excision repair cross-complementing group 1 (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) are important components of the DNA repair, considered as prognostic and predictive biomarkers in various cancer types. The main goal of the present study was to investigate the ERCC1 and RRM1 expression and their potential impact on outcome in this tumor. A series of 73 MPM, mainly treated with a platin-based regimen, was collected and the immunohistochemistry tests were performed to assess ERCC1 and RRM1 expression. In addition, a multiplex immunohistochemistry has been validated to detect simultaneously the 2 proteins on the same slide. In our series, 36 of 73 cases showed ERCC1 expression and 55 of 73 showed RRM1 expression. The double immunohistochemical staining showed the coexpression of ERCC1/RRM1 in 34 of 73 cases. A significant association between ERCC1 and RRM1 expression was observed in our series (P<0.05). Patients with ERCC1/RRM1 coexpression experienced shorter median overall survival (6.6 vs. 13.8 mo, log-rank=7688; P=0.006). Our results suggest that the coexpression of ERCC1/RRM1 could define a group of MPM patients with the worst prognosis who should need likely alternative treatment. In conclusion, we propose the putative usefulness of ERCC1/RRM1 coexpression as prognostic biomarkers for overall survival in MPM.
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: Mar 24, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.